Stock News•2 months ago
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Amneal (AMRX) is expanding into GLP-1 manufacturing and biosimilars via partnerships and acquisitions, aiming to strengthen its higher-value product portfolio.
MarketLens
Has Amphastar Pharmaceuticals Bottomed Out After Its Steep Decline
3 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
What Triggered Fermi's Steep Decline
4 months ago
What Triggered TIGR's Steep Decline
2 months ago
Category
You may also like
Stock News•3 months ago
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AnaptysBio (ANAB) shares may be approaching a technical floor after forming a hammer chart pattern following recent losses. This technical signal, paired with upward revisions in earnings estimates, s...
Stock News•3 months ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals reported Q1 2026 net revenues of $171.2 million. The company posted GAAP net income of $6.4 million, or $0.14 per share, while adjusted non-GAAP net income reached $19.5 mill...
Stock News•3 months ago
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Amphastar Pharmaceuticals (AMPH) is currently being evaluated through the Zacks Rank system, which prioritizes earnings estimate revisions. The analysis aims to identify potential value, growth, and m...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Here's Why Nvidia (NVDA) Fell More Than Broader Market
Stock News•1 hour ago
Pence: NVDA "Pivotal Chokepoint" of AI & Likes MSFT, AMZN, GOOGL in Mag 7
Stock News•2 hours ago
QYLD Holders Left $56,700 Per $10,000 on the Table Chasing Twelve Years of Monthly Income
Stock News•2 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alphabet Inc. - GOOG
Stock News•2 hours ago